Shire’s (SHPG) “Neutral” Rating Reiterated at JPMorgan Chase & Co.

Shire (NASDAQ:SHPG)‘s stock had its “neutral” rating reiterated by stock analysts at JPMorgan Chase & Co. in a note issued to investors on Tuesday.

Several other research firms have also recently issued reports on SHPG. Zacks Investment Research raised shares of Shire from a “sell” rating to a “hold” rating in a research report on Friday, October 27th. Royal Bank of Canada reissued a “buy” rating on shares of Shire in a research report on Thursday, November 16th. Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the stock a “buy” rating in a research report on Thursday, November 16th. Bank of America raised their target price on shares of Shire from $236.00 to $237.00 and gave the stock a “buy” rating in a research report on Monday, February 5th. Finally, Cowen set a $225.00 target price on shares of Shire and gave the stock a “buy” rating in a research report on Sunday, October 29th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $205.00.

Shares of Shire (SHPG) opened at $134.06 on Tuesday. Shire has a 12 month low of $123.73 and a 12 month high of $192.15. The stock has a market cap of $40,337.85, a PE ratio of 9.54, a price-to-earnings-growth ratio of 0.75 and a beta of 1.41. The company has a current ratio of 0.98, a quick ratio of 0.52 and a debt-to-equity ratio of 0.55.

Shire (NASDAQ:SHPG) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.86 by $0.12. Shire had a net margin of 28.17% and a return on equity of 14.75%. The company had revenue of $4.14 billion for the quarter. During the same period in the prior year, the business earned $3.37 earnings per share. Shire’s revenue for the quarter was up 8.9% on a year-over-year basis. sell-side analysts predict that Shire will post 15.27 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of SHPG. Raymond James Financial Services Advisors Inc. raised its holdings in Shire by 6.2% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 6,492 shares of the biopharmaceutical company’s stock valued at $1,073,000 after buying an additional 381 shares during the period. Sterling Capital Management LLC purchased a new position in Shire in the second quarter valued at approximately $299,000. Dynamic Technology Lab Private Ltd purchased a new position in Shire in the second quarter valued at approximately $406,000. Fisher Asset Management LLC raised its holdings in Shire by 2.9% in the third quarter. Fisher Asset Management LLC now owns 57,419 shares of the biopharmaceutical company’s stock valued at $8,793,000 after buying an additional 1,619 shares during the period. Finally, Osborne Partners Capital Management LLC raised its holdings in Shire by 5.2% in the third quarter. Osborne Partners Capital Management LLC now owns 38,500 shares of the biopharmaceutical company’s stock valued at $5,896,000 after buying an additional 1,905 shares during the period. Hedge funds and other institutional investors own 20.92% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Shire’s (SHPG) “Neutral” Rating Reiterated at JPMorgan Chase & Co.” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/20/shires-shpg-neutral-rating-reiterated-at-jpmorgan-chase-co.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply